medium-spiny-neurons-huntington-disease

Migration, Crosslink

📖

medium-spiny-neurons-huntington-disease

active

wiki page Created: 2026-04-02T07:19:38 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-cell-types-medium-spiny-neurons-hun

📖 Wiki Page

cell_type3029 wordssynced 2026-04-02

Striatal Medium Spiny Neurons in Huntington's Disease

Overview

Striatal medium spiny neurons (MSNs) constitute the primary output projection neurons of the striatum, representing approximately 90-95% of the total neuronal population in this critical basal ganglia structure. These neurons serve as the central hub for processing information flowing from the cerebral cortex and thalamus to the output nuclei of the basal ganglia, ultimately influencing motor control, procedural learning, habit formation, and goal-directed behavior. In Huntington's disease (HD), MSNs undergo selective and progressive degeneration that represents the hallmark neuropathological feature of the disorder and underlies the characteristic motor, cognitive, and psychiatric manifestations of the disease. PMID: 32681824

The importance of MSN degeneration in HD cannot be overstated. The striatum, and particularly the MSN population, serves as the primary site of neuropathological change in HD, with postmortem studies demonstrating 50-80% loss of these neurons even in early disease stages. This preferential vulnerability of MSNs results from a combination of factors including cell-autonomous toxicity from mutant huntingtin (mHTT) protein, non-cell-autonomous effects from supporting glial cells, and circuit-level vulnerabilities arising from the specific connectivity patterns of these neurons. Understanding the molecular and cellular mechanisms underlying MSN degeneration is essential for developing disease-modifying therapies that can slow or halt disease progression.

...

Striatal Medium Spiny Neurons in Huntington's Disease

Overview

Striatal medium spiny neurons (MSNs) constitute the primary output projection neurons of the striatum, representing approximately 90-95% of the total neuronal population in this critical basal ganglia structure. These neurons serve as the central hub for processing information flowing from the cerebral cortex and thalamus to the output nuclei of the basal ganglia, ultimately influencing motor control, procedural learning, habit formation, and goal-directed behavior. In Huntington's disease (HD), MSNs undergo selective and progressive degeneration that represents the hallmark neuropathological feature of the disorder and underlies the characteristic motor, cognitive, and psychiatric manifestations of the disease. PMID: 32681824

The importance of MSN degeneration in HD cannot be overstated. The striatum, and particularly the MSN population, serves as the primary site of neuropathological change in HD, with postmortem studies demonstrating 50-80% loss of these neurons even in early disease stages. This preferential vulnerability of MSNs results from a combination of factors including cell-autonomous toxicity from mutant huntingtin (mHTT) protein, non-cell-autonomous effects from supporting glial cells, and circuit-level vulnerabilities arising from the specific connectivity patterns of these neurons. Understanding the molecular and cellular mechanisms underlying MSN degeneration is essential for developing disease-modifying therapies that can slow or halt disease progression.

This page provides a comprehensive analysis of MSN biology, the specific mechanisms of vulnerability in HD, the differential susceptibility of MSN subtypes, and current and emerging therapeutic strategies aimed at preserving these critical neurons.

Cellular Biology of Medium Spiny Neurons

Morphological Characteristics

Medium spiny neurons are characterized by their relatively small cell bodies (soma diameter of 10-20 μm), medium-length dendritic trees, and dense populations of dendritic spines. These spines, which are the primary sites of excitatory synaptic input from cortical and thalamic afferents, give MSNs their distinctive appearance under histological examination and are essential for their normal function. The dendritic arborization of MSNs extends throughout the striatum, with individual neurons potentially receiving thousands of synaptic contacts from converging excitatory inputs.

The axonal projections of MSNs are extensive and highly organized. Each MSN projects to a single target nucleus—the substantia nigra pars reticulata (SNr) or the internal segment of the globus pallidus (GPi)—forming the so-called direct and indirect pathways based on their axonal targets and neurochemical properties. The precision of this projection system is critical for normal basal ganglia function, as MSNs integrate complex patterns of excitatory input and convert these patterns into specific patterns of inhibitory output that influence motor program selection and execution.

Neurochemical Subtypes

MSNs are classically divided into two major neurochemical subtypes based on their expression of dopamine receptors and peptide co-transmitters:

D1-MSNs (Direct Pathway): These neurons express D1 dopamine receptors and substance P, and project directly to the output nuclei of the basal ganglia (SNr and GPi). Activation of D1-MSNs promotes movement by facilitating thalamocortical activity, and this pathway is crucial for motor learning and the selection of appropriate behavioral responses. In HD, D1-MSNs exhibit early and progressive degeneration, contributing to the motor dysfunction characteristic of the disorder.

D2-MSNs (Indirect Pathway): These neurons express D2 dopamine receptors and enkephalin, and project to the external segment of the globus pallidus (GPe). The indirect pathway normally suppresses unwanted movements by inhibiting thalamic activity through the GPe-subthalamic nucleus-SNr/GPi circuit. D2-MSNs are also vulnerable in HD, though evidence suggests they may be relatively spared compared to D1-MSNs in early disease stages.

The differential vulnerability of D1- and D2-MSNs has significant therapeutic implications. The early loss of D1-MSNs may contribute to bradykinesia and impaired movement initiation, while relative sparing of D2-MSNs may underlie the development of chorea and other hyperkinetic movements in early HD. As disease progresses, both populations undergo degeneration, leading to the mixed motor phenotype observed in moderate to advanced disease stages. PMID: 38291334

Electrophysiological Properties

MSNs exhibit distinctive electrophysiological properties that reflect their role as integration devices within the basal ganglia circuit. In the resting state, these neurons show a characteristic low-frequency firing pattern with irregular pauses, reflecting the balance of excitatory and inhibitory inputs they receive. Cortical stimulation can evoke complex responses that include combinations of excitatory post-synaptic potentials (EPSPs), inhibitory post-synaptic potentials (IPSPs), and plateau potentials mediated by voltage-gated calcium channels.

The membrane properties of MSNs include:

High input resistance (tens of MΩ)
Depolarized resting membrane potential (approximately -80 mV)
Prominent hyperpolarization-activated currents (Ih)
NMDA receptor-mediated synaptic responses
D1 and D2 dopamine receptor modulation of excitability

In HD, multiple alterations in MSN electrophysiology have been documented, including changes in resting membrane potential, altered firing rates and patterns, impaired synaptic integration, and abnormal responses to dopamine receptor activation. These electrophysiological changes often precede frank neuronal loss and may represent therapeutic targets for early intervention.

Molecular Mechanisms of MSN Vulnerability in Huntington's Disease

Mutant Huntingtin Toxicity

The fundamental cause of MSN degeneration in HD is the toxic gain-of-function conferred by mutant huntingtin protein, which results from CAG trinucleotide repeat expansion in the HTT gene. The expanded polyglutamine tract in mHTT leads to protein misfolding, aggregation, and interference with multiple cellular processes essential for neuronal survival. MSNs appear to be particularly sensitive to mHTT toxicity through several interconnected mechanisms:

Transcriptional Dysregulation: mHTT interferes with normal gene expression by sequestering transcription factors and co-activators, including specificity protein 1 (Sp1), TATA-binding protein (TBP), and nuclear factor kappa-B (NF-κB). This transcriptional disruption affects the expression of genes essential for neuronal function, including those encoding:

Neurotrophic factors and their receptors
Neurotransmitter receptors and transporters
Proteins involved in synaptic function
Anti-apoptotic proteins

The loss of normal transcriptional programs creates a chronic state of cellular stress that progressively impairs neuronal function and ultimately triggers cell death pathways.

Impaired Protein Homeostasis: The accumulation of mHTT aggregates in the cytoplasm and nucleus interferes with the ubiquitin-proteasome system and autophagy, compromising the cell's ability to clear damaged proteins and organelles. MSNs, with their high metabolic demands and extensive protein synthesis requirements, are particularly vulnerable to disruptions in protein quality control.

Axonal Transport Defects: mHTT directly binds to microtubule-based motor proteins and interferes with axonal transport of synaptic vesicles, organelles, and neurotrophic factors. The long axonal projections of MSNs make them especially susceptible to transport deficits, which compromise synaptic function and lead to "dying-back" degeneration.

Energy Metabolism Deficits

MSNs have high baseline energy requirements due to their constant tonic activity and the ATP-demanding processes of maintaining ionic gradients, neurotransmitter synthesis, and vesicle cycling. This high metabolic demand makes them vulnerable to any disruption in cellular energy production: PMID: 29945611

Mitochondrial Dysfunction: Multiple studies have demonstrated mitochondrial abnormalities in HD, including:

Reduced complex I, II/III, and IV activity
Impaired mitochondrial calcium handling
Altered mitochondrial dynamics (fusion/fission)
Decreased mitochondrial DNA repair capacity
Increased sensitivity to mitochondrial permeability transition

These deficits are particularly pronounced in MSNs, which show greater mitochondrial impairment than other striatal neuronal populations in HD models.

ATP Depletion: The combination of transcriptional dysfunction (affecting mitochondrial biogenesis), impaired mitophagy (accumulating damaged mitochondria), and direct mitochondrial toxicity from mHTT leads to progressive ATP depletion in MSNs. This energy crisis impairs the ATP-dependent processes essential for neuronal survival, including:

Ion pump function (Na+/K+ ATPase, Ca2+ ATPases)
Neurotransmitter synthesis and vesicle refilling
Protein synthesis and folding
Membrane lipid synthesis

Excitotoxicity

Excitotoxicity has long been implicated in the pathogenesis of HD and represents a critical mechanism of MSN degeneration. Several factors contribute to pathological activation of glutamate receptors in HD:

Cortical Overdrive: The excitatory glutamatergic inputs from the cortex to the striatum are hyperactive in HD, providing excessive stimulation to MSNs. This may result from cortical dysfunction in HD or from loss of corticostriatal inhibitory feedback circuits.

Receptor Alterations: MSNs in HD show changes in glutamate receptor expression and function, including:

Increased NMDA receptor density and function
Altered AMPA receptor subunit composition
Dysregulated mGluR5 signaling
Impaired glutamate transporter function

Calcium Homeostasis: mHTT disrupts intracellular calcium regulation through multiple mechanisms, including direct interaction with calcium channels, impaired endoplasmic reticulum calcium handling, and mitochondrial calcium overload. The resulting calcium dysregulation activates deleterious downstream pathways including:

Calpain activation and proteolysis
Caspase activation and apoptosis
Nitric oxide synthase activation
Generation of reactive oxygen species

Synaptic Dysfunction and Dendritic Spine Loss

One of the earliest and most characteristic pathological changes in HD MSNs is the loss of dendritic spines, which begins in presymptomatic disease stages and progresses with disease severity. This synaptic pathology results from multiple mechanisms: PMID: 26740655

Synaptic Protein Dysregulation: mHTT interferes with the expression and function of proteins essential for synaptic structure and function, including:

Postsynaptic density proteins (PSD-95, NMDA receptor subunits)
Synaptic scaffolding proteins
Spine morphogenesis regulators (Rho GTPases, cofilin)

Neurotrophic Factor Deficits: Brain-derived neurotrophic factor (BDNF), which is essential for MSN survival and synaptic maintenance, is reduced in HD due to impaired cortical production, disrupted axonal transport, and altered TrkB receptor signaling. The loss of BDNF support contributes to synaptic dysfunction and dendritic spine loss.

Actin Cytoskeleton Abnormalities: The actin cytoskeleton of dendritic spines is reorganized in HD, with decreased filamentous actin and increased globular actin. This cytoskeletal disruption compromises spine stability and leads to spine shrinkage and loss.

The functional consequences of spine loss are profound. Each dendritic spine represents a distinct excitatory synapse, and the 30-50% spine loss observed in HD animal models translates to a corresponding reduction in excitatory synaptic input. This synaptic impairment contributes to the deficits in information processing, learning, and motor control that characterize HD.

Differential MSN Subtype Vulnerability

D1-MSN Vulnerability

The direct pathway MSNs expressing D1 receptors show particular early vulnerability in HD. This selective susceptibility results from multiple factors:

Transcriptional Program Susceptibility: D1-MSNs express a distinct set of genes that may be particularly affected by mHTT-mediated transcriptional dysregulation. The loss of D1 receptor signaling-related gene expression compromises cell survival pathways that are specifically important for this population.

Dopamine Toxicity: While dopamine is typically neuroprotective through D1 receptor signaling, in the context of mHTT toxicity, dopamine metabolism generates reactive oxygen species that may exacerbate oxidative stress in D1-MSNs.

Huntingtin Aggregation: Some studies suggest that mHTT aggregates may form more readily in D1-MSNs, possibly reflecting cell-type-specific differences in protein homeostasis mechanisms. PMID: 27818324

The early loss of D1-MSNs contributes to the bradykinesia and impaired movement initiation seen in HD patients, as this pathway is essential for initiating goal-directed movements.

D2-MSN Vulnerability

D2-MSNs also degenerate in HD but may show relative sparing in early disease stages. The mechanisms underlying this differential vulnerability include:

Neuroprotective Signaling: D2 receptor activation may provide some neuroprotection through signaling pathways that promote cell survival. The relatively intact D2-MSN population in early HD may reflect continued signaling through these pathways.

Enkephalin Expression: The neuropeptide enkephalin, which is specifically expressed in D2-MSNs, may have some neuroprotective properties that slow degeneration in this population.

Circuit-Level Factors: The indirect pathway receives different patterns of synaptic input than the direct pathway, and these circuit-level differences may influence vulnerability.

As disease progresses, D2-MSNs also undergo significant degeneration, contributing to the loss of movement suppression and the emergence of chorea and dyskinesias.

Clinical Manifestations of MSN Dysfunction

Motor Symptoms

The degeneration of MSNs in HD produces a characteristic motor syndrome that evolves with disease progression:

Chorea: The earliest motor manifestations in most HD patients are choreiform movements—brief, random, involuntary movements that appear fidgety and flow from one body part to another. This hyperkinetic movement disorder results from relative sparing of D2-MSNs (indirect pathway) compared to D1-MSNs (direct pathway), leading to reduced inhibition of thalamocortical excitation. Chorea typically emerges in early disease and may become less prominent as disease progresses and both MSN populations degenerate. PMID: 41090351

Bradykinesia: As disease advances, bradykinesia (slowness of movement) becomes more prominent. This results from progressive loss of both D1- and D2-MSNs, compromising both movement initiation and movement suppression. The late-stage HD patient shows a mixed hyperkinetic-bradykinetic syndrome.

Dystonia: Involuntary tonic contractions producing abnormal postures or sustained movements emerge in middle disease stages. This results from the breakdown of the normal balance between direct and indirect pathway activity.

Motor Learning Deficits: MSNs are essential for procedural learning and habit formation. Their dysfunction in HD produces profound deficits in learning new motor skills and forming habitual behaviors.

Oculomotor Abnormalities: MSNs in the oculomotor circuit are affected in HD, producing slowed saccades, impaired smooth pursuit, and difficulty with antisaccade tasks.

Cognitive Deficits

The cognitive impairment in HD reflects the critical role of the striatum and MSNs in executive function, working memory, and decision-making:

Executive Dysfunction: MSNs support the cortical-striatal-thalamic circuits that underlie executive processes including planning, set-shifting, cognitive flexibility, and inhibitory control. MSN degeneration produces characteristic executive deficits that often precede motor symptoms.

Working Memory Deficits: The integration and maintenance of information in working memory depends on intact MSN function. HD patients show deficits in both spatial and verbal working memory.

Decision-Making Impairment: MSNs are essential for value-based decision-making and reward learning. Their dysfunction contributes to the poor decision-making seen in HD patients, including both behavioral and economic choices. PMID: 40090469

Procedural Learning: The striatal MSNs are critical for procedural learning and habit formation. HD patients show early deficits in learning new motor skills and developing habits, even before formal motor symptoms emerge.

Psychiatric Manifestations

MSN dysfunction contributes to the psychiatric symptoms of HD, which often precede motor and cognitive manifestations:

Depression: Striatal dysfunction affects limbic circuits involved in mood regulation, contributing to the high prevalence of depression in HD (estimated at 40-50% across disease stages).

Anxiety: The uncertainty and unpredictability of HD progression may interact with underlying striatal dysfunction to produce anxiety symptoms.

Irritability and Aggression: Dysregulation of limbic striatal circuits contributes to emotional lability and aggressive outbursts in some HD patients.

Apathy: The most common psychiatric symptom in HD, apathy reflects dysfunction in the motivational circuits that depend on intact MSN function, particularly the dopaminergic projections to the ventral striatum.

Therapeutic Strategies

Symptomatic Treatments

Current treatments for HD address specific symptoms but do not modify disease progression:

Tetrabenazine and Deutetrabenazine: These VMAT2 inhibitors reduce chorea by depleting dopamine from presynaptic terminals. While effective for chorea management, they do not address the underlying MSN degeneration or other symptoms. PMID: 21345011

Antipsychotics: Drugs such as haloperidol, olanzapine, and risperidone can reduce chorea and address psychiatric symptoms. Their use is limited by side effects including sedation, weight gain, and tardive dyskinesia.

Antidepressants: SSRIs and other antidepressants are used to treat depression and anxiety in HD.

Cognitive Enhancers: No specific treatments for HD-related cognitive impairment have demonstrated clear efficacy.

Disease-Modifying Approaches

Multiple strategies aimed at modifying disease progression by preserving MSNs are in development:

Huntingtin-Lowering Therapies: ASOs (such as tominersen) and RNAi approaches that reduce mHTT expression represent the most advanced disease-modifying strategies. By reducing the primary toxic protein, these approaches may slow or halt MSN degeneration. Several clinical trials have demonstrated safety and target engagement, though efficacy results have been mixed.

Neuroprotective Agents: Multiple compounds targeting specific mechanisms of MSN vulnerability are in development:

Mitochondrial protectants (CoQ10, creatine)
Anti-excitotoxic agents (memantine, amantadine)
Antioxidants (vitamin E, N-acetylcysteine)
Neurotrophic factors (BDNF mimetics)

Cell Replacement Therapy: Transplantation of MSN progenitors or stem cell-derived MSNs represents a potential approach to replace lost neurons. Early clinical trials have demonstrated safety, but functional benefits have been limited by poor survival and integration of transplanted cells.

Gene Therapy: Delivery of neuroprotective genes (BDNF, GDNF, anti-apoptotic proteins) to the striatum via AAV vectors is in preclinical and early clinical development.

[Striatal Cholinergic Interneurons in Huntington's Disease](/cell-types/striatal-cholinergic-interneurons-huntingtons)
[GABAergic Striatal Interneurons in Huntington's Disease](/cell-types/gabaergic-striatal-interneurons-huntingtons)
[Cortical Neurons in Huntington's Disease](/cell-types/cortical-neurons-huntingtons-disease)

[Excitotoxicity Pathway](/mechanisms/excitotoxicity-pathway)
[Mitochondrial Dysfunction in Huntington's Disease](/mechanisms/mitochondrial-dysfunction-huntingtons)
[Neuroinflammation in Huntington's Disease](/mechanisms/neuroinflammation-huntingtons)
[Dopamine Signaling in Huntington's Disease](/mechanisms/dopaminergic-neurodegeneration)

[Huntingtin (HTT protein)](/proteins/huntingtin)
[Brain-Derived Neurotrophic Factor (BDNF proteins/bdnf-protein)
[D1 Dopamine Receptor (DRD1 proteins/d1-dopamine-receptor)
[D2 Dopamine Receptor (DRD2 proteins/d2-dopamine-receptor)

[Huntington's Disease](/diseases/huntingtons)
[Alzheimer's Disease](/diseases/alzheimers)
[Parkinson's Disease](/diseases/parkinsons-disease)

[Striatum](/brain-regions/striatum)
[Caudate Nucleus](/brain-regions/caudate-nucleus)
[Putamen](/brain-regions/putamen)
[Globus Pallidus](/brain-regions/globus-pallidus)
[Substantia Nigra](/brain-regions/substantia-nigra)

Summary

Striatal medium spiny neurons represent the primary output neurons of the basal ganglia and undergo selective degeneration in Huntington's disease. The vulnerability of MSNs results from multiple interconnected mechanisms, including direct toxicity from mutant huntingtin protein, transcriptional dysregulation, energy metabolism deficits, excitotoxic stress, and synaptic dysfunction. D1-MSNs of the direct pathway show earlier and more severe vulnerability than D2-MSNs, contributing to the characteristic progression from hyperkinetic (chorea) to mixed (chorea plus bradykinesia) motor dysfunction. The loss of MSNs underlies not only motor symptoms but also cognitive deficits and psychiatric manifestations. Current treatments address symptoms but not disease progression, while multiple disease-modifying approaches—including huntingtin-lowering therapies, neuroprotective agents, and cell replacement—are in development. Understanding the specific mechanisms of MSN vulnerability remains essential for developing effective therapies that can preserve these critical neurons in HD patients.

Pathway Diagram

Mermaid diagram (expand to render)

References

[Vonsattel JP, et al. Neuropathological classification of Huntington's disease (1985)](https://pubmed.ncbi.nlm.nih.gov/4012558/)

[Reiner A, et al. Differential regulation of striatal proenkephalin mRNA and peptide levels in Huntington's disease (1988)](https://pubmed.ncbi.nlm.nih.gov/2903275/)

[Graybiel AM. The basal ganglia and chunking (2000)](https://pubmed.ncbi.nlm.nih.gov/10841806/)

[Cepeda C, et al. Striatal neuronal dysfunction in Huntington's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17400373/)

[Ross CA, et al. Huntington disease: Pathogenesis, pathophysiology, and therapy (2014)](https://pubmed.ncbi.nlm.nih.gov/24891600/)

[Stahl K, et al. Neuronal vulnerability in Huntington's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32801094/)

[Plotkin JD, et al. Impaired mitochondrial dynamics and energy deficit in Huntington's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/24383704/)

[Gu X, et al. Pathological cell-cell interactions between mutant huntingtin and striatal neurons (2015)](https://pubmed.ncbi.nlm.nih.gov/25621496/)

[Plotkin JD, et al. Molecular mechanisms of striatal neuron death in Huntington's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24815330/)

[Dombrowski A, et al. Dendritic spine loss in Huntington's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25061086/)

[Singh S, et al. Synaptic dysfunction in Huntington's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31260058/)

[Taylor AR, et al. Striatal medium spiny neuron subtypes in Huntington's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32344428/)

[Richfield EK, et al. Behavioral and regional neuronal selectivity in Huntington's disease (2002)](https://pubmed.ncbi.nlm.nih.gov/12460674/)

[Garden GA, et al. Molecular pathways in Huntington's disease (2002)](https://pubmed.ncbi.nlm.nih.gov/12009766/)

[Cha JH, et al. Altered neurotransmitter receptor expression in Huntington's disease (2000)](https://pubmed.ncbi.nlm.nih.gov/10715549/)

[Levy R, et al. Striatal dysfunction in Huntington's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17045516/)

[Ahmad MH, et al. Resting state functional connectivity in Huntington's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/30344646/)

[Kumar A, et al. Biomarkers for Huntington's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32028042/)

[Sanders J, et al. Huntingtin lowering therapies for Huntington's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32644291/)

[Leavitt B, et al. Tetrabenazine in Huntington's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33247568/)

📖 View canonical wiki page →

Related Entities

cell-types-medium-spiny-neurons-huntington-disease

▸Metadataorigin_type: v1_polymorphic_backfill

slug	cell-types-medium-spiny-neurons-huntington-disease
kg_node_id	None
entity_type	cell_type
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-86265f41f739
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'cell-types-medium-spiny-neurons-huntington-disease'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

30

Outgoing

234

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

medium-spiny-neurons-huntington-disease

Striatal Medium Spiny Neurons in Huntington's Disease

Overview

Striatal Medium Spiny Neurons in Huntington's Disease

Overview

Cellular Biology of Medium Spiny Neurons

Morphological Characteristics

Neurochemical Subtypes

Electrophysiological Properties

Molecular Mechanisms of MSN Vulnerability in Huntington's Disease

Mutant Huntingtin Toxicity

Energy Metabolism Deficits

Excitotoxicity

Synaptic Dysfunction and Dendritic Spine Loss

Differential MSN Subtype Vulnerability

D1-MSN Vulnerability

D2-MSN Vulnerability

Clinical Manifestations of MSN Dysfunction

Motor Symptoms

Cognitive Deficits

Psychiatric Manifestations

Therapeutic Strategies

Symptomatic Treatments

Disease-Modifying Approaches

Summary

Pathway Diagram

References

💬 Discussion

📗 Cite This Artifact

medium-spiny-neurons-huntington-disease

Striatal Medium Spiny Neurons in Huntington's Disease

Overview

Striatal Medium Spiny Neurons in Huntington's Disease

Overview

Cellular Biology of Medium Spiny Neurons

Morphological Characteristics

Neurochemical Subtypes

Electrophysiological Properties

Molecular Mechanisms of MSN Vulnerability in Huntington's Disease

Mutant Huntingtin Toxicity

Energy Metabolism Deficits

Excitotoxicity

Synaptic Dysfunction and Dendritic Spine Loss

Differential MSN Subtype Vulnerability

D1-MSN Vulnerability

D2-MSN Vulnerability

Clinical Manifestations of MSN Dysfunction

Motor Symptoms

Cognitive Deficits

Psychiatric Manifestations

Therapeutic Strategies

Symptomatic Treatments

Disease-Modifying Approaches

Cross-Linking and Related Content

Related Cell Types

Related Mechanisms

Related Proteins

Related Diseases

Related Brain Regions

Summary

Pathway Diagram

References

💬 Discussion